An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of Doxil/Caelyx and Yondelis to Doxil/Caelyx Alone in Subjects With Advanced Relapsed Ovarian Cancer.

Trial Profile

An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of Doxil/Caelyx and Yondelis to Doxil/Caelyx Alone in Subjects With Advanced Relapsed Ovarian Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Trabectedin (Primary) ; Dexamethasone; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Johnson & Johnson
  • Most Recent Events

    • 24 May 2017 Results comparing Trabectedin-Based Versus Platinum-Based Treatment in Relapsed, Partially Platinum Sensitive Ovarian Cancer patients from two randomised trials (OVA-301 and CALYPSO) presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 31 Oct 2016 Data from this trial presented at 16th Biennial International Gynecologic Cancer Society Meeting (IGCS), as per PharmaMar media release.
    • 30 May 2014 Results on overall survival from platinum-resistant patients retreated with platinum after OVA301 presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top